European Journal of Hospital Pharmacy: Science and Practice最新文献

{"title":"4CPS-297 Spinal cord aplasia caused by 6-mercaptopurine in a Caucasian girl with acute lymphoblastic leukaemia and homozygous mutation in nudix hydrolase 15: case report","authors":"LE Pineda Lancheros, C. Pérez Ramírez, N. Moreno Toro, A. Espinosa Rodriguez, A. Sánchez Martín","doi":"10.1136/EJHPHARM-2021-EAHPCONF.129","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.129","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79731357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2SPD-047 New requirements of outpatients in the COVID-19 era: adapting pharmaceutical care","authors":"LF Esther, Blessy Jose, D. Maria, J. Becerra, LS Beatriz, LG Natalia, S. Ramón, AV Amaya, S. Maite, NS Lorena","doi":"10.1136/EJHPHARM-2021-EAHPCONF.30","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.30","url":null,"abstract":"Background and importanceAdapt the outpatients care activity to the scenario arising out of the COVID-19 pandemic Aim and objectivesReorganisation of the area, non in-person consultation, medication home delivery (MHD) and reduce patient attendance at day hospitals Material and methodsPhase 1 (P1): reinforcement of human resources, increase and easy the presential and telepharmacy schedule, adaptation of the facilities Phase 2 (P2): advanced preparation of the medication, MHD, substitution of intravenous treatments by subcutaneous treatments The telepharmacy and MHD were conducted at patients’ request Delivery routes and alternative urgent delivery systems were established P1 activities began 2 weeks prior to the announcement of the State of Alarm (SoA, 16 March 2020) and P2 began and continues for vulnerable patients Our project is currently underway in a proactive, selective and continuous way ResultsActivities were analysed during 2020, weeks 12–19 (16 March to 10 May 2020) and compared with theoretical activity during the same period in 2019, with an increase in activity (+21%) The difference between the sum of in-person and telematic consultations and the theoretical consultations for the period was named after omitted consultations Overall activity in weeks 12–19 was 5550 consultations, of which 4414 (79 5%) were in-person and 1136 (20 5%) telematic The estimated activity would have been 7030 consultations, and 1480 (21% of the theoretical ones) have been omitted In-person activity decreased from 5973 patients between weeks 12 and 19 in 2019 to 4414 in 2020 (−23 3%) Distribution of the 1136 MHD: week 12 (30), week 13 (131), week 14 (232), week 15 (190), week 16 (168), week 17 (155), week 18 (115) and week 19 (115) Waiting times for in-person consultation were reduced from an average of 5 2 min/patient in the pre-alarm period to 3 min during the alarm (−42 3%) Conclusion and relevanceOur data may be used to detect areas for improvement;consultations should be made proactively and tools are needed to qualitatively analyse omitted activity A system is needed to account for tele-assistance that has not resulted in dispensing medication or MHD References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83432088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2SPD-030 Positioning of doravirine in the pharmacotherapeutic guide of a third level hospital","authors":"A. Alvarez, A. L. Alarcón, R. Díez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.13","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.13","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88545207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-397 Assessment of pharmaceutical interventions in an intensive care unit after computerised physician order entry system implementation","authors":"M. Rubio, MB Fuentes Ibáñez, M. Padilla","doi":"10.1136/EJHPHARM-2021-EAHPCONF.229","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.229","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88581614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-310 Tofacitinib effectiveness and safety results: real world data","authors":"R. A. Sanchez, C. Castaño-Amores, P. N. Gómez, A. R. Delgado, S. P. Haro, P. Rodríguez, J. C. Barrera","doi":"10.1136/EJHPHARM-2021-EAHPCONF.142","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.142","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77878946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-291 Palbociclib: early neutropenia as a pharmacodynamic marker in a real world setting?","authors":"X. Fernández-Sala, ME Navarrete-Rouco, L. Río-No, J. Albanell, D. Conde-Estévez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.123","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.123","url":null,"abstract":"","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74701811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-279 Cancer pain management approach considering potential drug interactions in patients receiving oral antitumour treatment","authors":"R. D. Fernández, F. Fraga, M. García, T. M. García","doi":"10.1136/EJHPHARM-2021-EAHPCONF.111","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.111","url":null,"abstract":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI; ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191. For each patient, drug-to-drug interactions for 17 analgesics were evaluated using Lexicomp® database: Risk A (no interaction) B (no action needed) C (monitor therapy) D (modify regimen) X (avoid combination)","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72610784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-348 The hospital pharmacy in the creation of clean circuits in the face of COVID-19","authors":"R. Seisdedos, I. L. Manzano, C. G. Fernández","doi":"10.1136/EJHPHARM-2021-EAHPCONF.180","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.180","url":null,"abstract":"Background and importanceThe SARS-CoV-2 health crisis unleashed in Spain in March 2020 forced hospitals to urgently reorganise and adapt in an unprecedented way One of the strategies carried out was the establishment of ‘clean’ circuits and hospitals from SARS-CoV-2 Aim and objectivesTo describe the organisational changes of a pharmacy service of a SARS-CoV-2 ‘clean’ hospital and to measure their impact Material and methodsThe study was carried out in an 86 bed hospital (non-COVID-19 use) dependent on a 652 bed university hospital (with care for COVID-19 patients), located in a different location, from 11 March, when the WHO declared the pandemic, to 21 June 2020, ending the state of alarm The activity was compared with the same period in the previous year Outpatient pharmaceutical care unit (OPCU) patient surveys were conducted to measure impact The staff was temporarily reinforced with a specialist in the hospital pharmacy ResultsThe following implementations were carried out:Opening of OPCU, with 886 dispensations to 448 patients, compared with 34 dispensations to 9 patients the previous year 60 surveys were conducted, where 60% of patients expressed that had they had to travel to their usual hospital during the pandemic, they would not have collected their medication Furthermore, 93% of patients said they felt safe in their visit to the new OPCU Satisfaction evaluation was excellent (average 10/10) Medicalisation of a 165 bed nursing home Referral of day hospital patients 570 dispensations were made to 191 patients compared with 154 dispensations to 44 patients in 2019 Transfer of the oncology hospital ward Total stays increased from 3253 in the previous year to 4326 (33% increase) Creation of a specific respiratory emergency service, where SARS–CoV–2 positive cases were referred to the referral hospital Conclusion and relevanceAmong the new circuits, opening of the OPCU stood out because of the avoidance of a large number of trips to a ‘dirty’ hospital in another town, the improvement in adherence and for the great organisational effort in a very short period of time The different measures allowed the non-COVID-19 activity to continue, minimising the risk of contagion for patients The health crisis due to SARS-CoV-2 has been a challenge and the hospital pharmacy has shown a great capacity for adaptation References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84230771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-219 Comparison of the number of parental nutrition prescriptions in 2020 during the COVID-19 pandemic with the same time period in 2019","authors":"I. Sollano-Sancho, B Bertran De Lis-Bartolome, P. San Miguel-Torvisco, I. Morona-Minguez, EP Gómez-Caballero, J. Solis-Olivares, I. Soto-Baselga, B. Rubio-Cebrián, G. Picazo-Sanchis, C. Moriel-Sánchez","doi":"10.1136/EJHPHARM-2021-EAHPCONF.51","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.51","url":null,"abstract":"Background and importanceThe pharmacy service (PS) is a cornerstone of the nutritional support of patients, especially those with special needs For this reason, it is necessary to create individualised nutrition following recommendations from scientific organisations, such as the European Society for Clinical Nutrition and Metabolism (ESPEN) Aim and objectivesTo analyse prescriptions of parental nutrition (PN) during the pandemic and compare them with those from the same time period in 2019 Material and methodsThis was a retrospective descriptive observational analysis of data from a secondary care hospital during March and April, both in 2019 and 2020 Demographic (age and sex) and clinical (length of PN and diagnosis) data were collected from medical records ResultsThere were 157 patients with PN during the period of study in 2020, 106 (67 5%) men with a median age of 67 years (IQR 14 5 years) In 2019, 64 patients received PN, 38 (59 4%) were men with a median age of 70 years (IQR 17) In 2020, 48 8% of patients with PN were under the critical care service (CCS), 30 6% internal medicine service (IMS) and 18 5% surgical service (SS);108 (68 8%) were diagnosed with COVID-19 In 2019, 15 6% of patients were under CCS, 25% IMS and 56 4% SS In 2020, 85 patients (54 1%) terminated PN due to health improvement and 60 (38 2%) died;in 2019, 54 (84 4%) improved and 9 (14 1%) died In 2020, the median age of deceased patients was 67 years (IQR 12 5 years) and in 2019 it was 77 years (IQR 9 5 years) The total number of PN prescribed during the periods of the study was 2121 in 2020 and 876 in 2019 Conclusion and relevanceIn the context of the SARS-CoV-2 pandemic, nearly half of all PN were prepared for CCS patients This increase in CCS patients in 2020 seems to explain the 10 year reduction in the median age of death and the increase in mortality In 2020, the number of PN prepared by the PS nearly tripled in comparison with the same period in 2019 They were individually adapted to each patient’s requirements, which led to a substantial increase in the care load and the preparation of the PN References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85417045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"4CPS-332 Tocilizumab for treating COVID pneumonia: analysis of effectiveness and security","authors":"C Del Pozo Carlavilla, M. Andújar, S. Paniagua, M Del Pozo Carlavilla, S. Sánchez, B. Serrano, J. Sanz, E. Martínez, H. Ayllón, M. S. Garrido","doi":"10.1136/EJHPHARM-2021-EAHPCONF.164","DOIUrl":"https://doi.org/10.1136/EJHPHARM-2021-EAHPCONF.164","url":null,"abstract":"Background and importanceTocilizumab (TCZ) is an immunosuppressor drug, IL-6 inhibitor, indicated for the treatment of rheumatoid arthritis and cytokine release syndrome associated with CAR T cell therapy It was proposed as a compassionate treatment for severe COVID-19 due to its potential benefit as anticytokine therapy with IL-6 as the target, one of the most relevant cytokines involved in the cytokine storm induced by COVID-19 Aim and objectivesThe main objective was to evaluate TCZ security and effectiveness in the treatment of COVID-19 pneumonia Material and methodsA retrospective observational study was conducted in patients with COVID-19 pneumonia treated with TCZ from 20 March to 20 May 2020 at a tertiary hospital Study variables were: age, sex, need for invasive and non-invasive ventilation, intubation days and oxygen therapy Days in inpatient care, admission to intensive care units (ICU) and time spent there, adverse reactions and deaths were also obtained Data were recollected from the electronic clinical records ResultsData from 59 COVID-19 patients were collected in this study between March and May 2020 Median age (max-min) was 62 4 (48–74) years and 76 3% of patients were men Comorbidities were: hypertension in 37 3%, dyslipidaemia in 20 3% and diabetes in 15 2% Six patients had asthma and 5 had cardiopathy 72 hours after TCZ administration, 54 2% of patients had respiratory improvement with a reduced need for oxygen therapy, 32 2% had stabilisation of their condition and 13 6% had worsening of their condition, requiring orotracheal intubation Seven days after TCZ administration, 44 had clinical improvement with a reduced need for oxygen therapy, 6 remained stable with VNI and 9 had worsening of their condition (6 passed out, 3 were admitted to the ICU) TCZ was well tolerated with no adverse effects detected 28 days after TCZ administration, mortality was 15 2%, 69 6% were discharged and 15 2% remained in hospital at the end of the study Conclusion and relevanceThe results of the study showed that TCZ was effective and safe in patients with COVID-19 pneumonia Patient outcomes were favourable in most cases During admission, patients showed clinical improvement with a reduced need for invasive ventilation and oxygen therapy Due to the potential bias (patients received different treatments before and after TCZ) and the small sample size, it is necessary to confirm these results in controlled clinical trials References and/or acknowledgementsConflict of interestNo conflict of interest","PeriodicalId":11991,"journal":{"name":"European Journal of Hospital Pharmacy: Science and Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79866517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}